Jiaxin Cao

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Venues

Signal transduction and targeted therapy

Cell death & disease

MedComm

This page only lists publications with an associated author ORCID identifier.

Publications

Zhonghan Zhang, Jinhui Xue, Yunpeng Yang, Wenfeng Fang, Yan Huang, Shen Zhao, Fan Luo, Jiaxin Cao, Kangmei Zeng, Wenjuan Ma, Jianhua Zhan, Feiteng Lu, Li Zhang, Hongyun Zhao
Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors. MedComm 5 (6) (2024)
Jiaxin Cao, Kangmei Zeng, Qun Chen, Ting Yang, Feiteng Lu, Chaozhuo Lin, Jianhua Zhan, Wenjuan Ma, Ting Zhou, Yan Huang, Fan Luo, Hongyun Zhao
PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma. Cell death & disease 15 (3) (2024)
Jiaxin Cao, Kangmei Zeng, Qun Chen, Ting Yang, Feiteng Lu, Chaozhuo Lin, Jianhua Zhan, Wenjuan Ma, Ting Zhou, Yan Huang, Fan Luo, Hongyun Zhao
PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma. Cell death & disease 15 (3) (2024)
Jiaxin Cao, Kangmei Zeng, Qun Chen, Ting Yang, Feiteng Lu, Chaozhuo Lin, Jianhua Zhan, Wenjuan Ma, Ting Zhou, Yan Huang, Fan Luo, Hongyun Zhao
PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma. Cell death & disease 15 (3) (2024)
Zhonghan Zhang, Jinhui Xue, Yunpeng Yang, Wenfeng Fang, Yan Huang, Shen Zhao, Fan Luo, Jiaxin Cao, Kangmei Zeng, Wenjuan Ma, Jianhua Zhan, Feiteng Lu, Li Zhang, Hongyun Zhao
Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors. MedComm 5 (6) (2024)
Yuxiang Ma, Jiaxin Cao, Yang Zhang, Qianwen Liu, Wenfeng Fang, Yunpeng Yang, Yuanyuan Zhao, Qing Yang, Hongyun Zhao, Li Zhang
Phase I study of camrelizumab in patients with advanced solid tumors. Signal transduction and targeted therapy 8 (1) (2023)
Yuxiang Ma, Jiaxin Cao, Yang Zhang, Qianwen Liu, Wenfeng Fang, Yunpeng Yang, Yuanyuan Zhao, Qing Yang, Hongyun Zhao, Li Zhang
Phase I study of camrelizumab in patients with advanced solid tumors. Signal transduction and targeted therapy 8 (1) (2023)
Yuxiang Ma, Jiaxin Cao, Yang Zhang, Qianwen Liu, Wenfeng Fang, Yunpeng Yang, Yuanyuan Zhao, Qing Yang, Hongyun Zhao, Li Zhang
Phase I study of camrelizumab in patients with advanced solid tumors. Signal transduction and targeted therapy 8 (1) (2023)
Yuxiang Ma, Jiaxin Cao, Yang Zhang, Qianwen Liu, Wenfeng Fang, Yunpeng Yang, Yuanyuan Zhao, Qing Yang, Hongyun Zhao, Li Zhang
Phase I study of camrelizumab in patients with advanced solid tumors. Signal transduction and targeted therapy 8 (1) (2023)
Yuxiang Ma, Jiaxin Cao, Yang Zhang, Qianwen Liu, Wenfeng Fang, Yunpeng Yang, Yuanyuan Zhao, Qing Yang, Hongyun Zhao, Li Zhang
Phase I study of camrelizumab in patients with advanced solid tumors. Signal transduction and targeted therapy 8 (1) (2023)

Jiaxin Cao.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jiaxin Cao